MBX Biosciences (NASDAQ: MBX) posts Q1 loss, cash funding plans into 2029
Rhea-AI Filing Summary
MBX Biosciences reported a first quarter 2026 net loss of $23.5M, similar to a $23.9M loss a year earlier, as it continues investing in its endocrine and metabolic pipeline. Cash, cash equivalents and marketable securities were $440.0M as of March 31, 2026, which the company expects will fund operations into 2029.
R&D expenses fell to $18.5M while G&A expenses rose to $8.8M, reflecting both lower trial costs and ongoing infrastructure build-out. MBX highlighted progress for once-weekly canvuparatide in hypoparathyroidism, including planned Phase 3 initiation in Q3 2026, expansion of its obesity portfolio around MBX 4291 and new candidates, and Phase 2 advancement of imapextide for post-bariatric hypoglycemia.
Positive
- None.
Negative
- None.
Insights
MBX posts steady losses but ends Q1 2026 with sizable cash and advancing late-stage programs.
MBX Biosciences reported a Q1 2026 net loss of $23.5M with operating expenses of $27.3M. R&D declined to $18.5M while G&A increased to $8.8M, consistent with a shift from heavy Phase 2 spending toward broader organizational build-out.
The company ended the quarter with $440.0M in cash, cash equivalents and marketable securities and expects this to fund operations into 2029. Pipeline catalysts include Phase 3 initiation for once-weekly canvuparatide in chronic hypoparathyroidism in Q3 2026, Phase 1 data for obesity candidate MBX 4291 in Q4 2026, additional obesity candidate nominations, and Phase 2a results for imapextide in post-bariatric hypoglycemia in Q2 2026.
The appointment of a Chief Commercial Officer adds launch-focused expertise ahead of potential late-stage progress. Overall, the combination of substantial cash runway and clearly dated clinical milestones sets up a multi-year development path, while outcomes will depend on future trial results and regulatory decisions.
8-K Event Classification
Key Figures
Key Terms
Phase 3 trial medical
once-weekly canvuparatide medical
Precision Endocrine Peptide (PEP™) platform medical
multiple ascending dose (MAD) portion medical
post-bariatric hypoglycemia (PBH) medical
End-of-Phase 2 meeting regulatory
Earnings Snapshot
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
||
Registrant’s Telephone Number, Including Area Code: |
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 2.02 Results of Operations and Financial Condition.
On May 7, 2026, MBX Biosciences, Inc. (the "Company") announced its financial results for the quarter ended March 31, 2026. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information included under Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1 attached hereto), is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
|
|
Exhibit No. |
Description |
99.1 |
Press Release Issued by MBX Biosciences, Inc. on May 7, 2026 |
104 |
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
MBX Biosciences, Inc. |
|
|
|
|
Date: |
May 7, 2026 |
By: |
/s/ P. Kent Hawryluk |
|
|
|
President and Chief Executive Officer (Principal Executive Officer) |
Exhibit 99.1
MBX Biosciences Reports First Quarter 2026 Financial Results and Corporate Highlights
Results from Phase 2 trial of once-weekly canvuparatide accepted for oral presentation at ENDO in June 2026
Phase 3 trial of once-weekly canvuparatide on track to initiate in Q3 2026
Appointment of Mark Soued as Chief Commercial Officer adds launch and commercialization expertise
Company to host Obesity Day on May 11th featuring initial blinded data from ongoing MBX 4291 Phase 1 trial and update on expanding obesity portfolio
$440.0 million in cash and investments expected to support operations into 2029
CARMEL, Ind., and BURLINGTON, Mass., May 7, 2026 (GLOBE NEWSWIRE) – MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today reported financial results for the first quarter ended March 31, 2026, and highlighted recent corporate progress.
“We continue to make excellent progress across our pipeline in 2026, including advancement toward initiation of our Phase 3 trial of once-weekly canvuparatide following a successful End-of-Phase 2 meeting with the FDA,” said Kent Hawryluk, President and Chief Executive Officer of MBX Biosciences. “Now we look forward to presenting our full Phase 2 Avail™ results, including one-year open-label extension data for canvuparatide, while continuing to advance a growing obesity pipeline enabled by our Precision Endocrine Peptide (PEP™) platform. With a world-class leadership team and a strong balance sheet, we are well positioned to execute on our goal of delivering improved, long-acting and well-tolerated peptide therapies for patients.”
First Quarter 2026 and Corporate Highlights
Once-Weekly Canvuparatide for Hypoparathyroidism
MBX 4291 and Expanding Obesity Pipeline
Corporate
Anticipated Milestones
Canvuparatide
MBX 4291 and Expanding Obesity Pipeline
Imapextide
First Quarter 2026 Financial Results
About MBX Biosciences
MBX Biosciences is a biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies based on its proprietary PEP™ platform, for the treatment of endocrine and metabolic disorders. The Company is advancing a pipeline of novel candidates for endocrine and metabolic disorders with clinically validated targets, established endpoints for regulatory approval, significant unmet medical needs and large potential market opportunities. The Company’s pipeline includes canvuparatide (MBX 2109) for the treatment of chronic hypoparathyroidism preparing for Phase 3 development; an obesity portfolio that includes MBX 4291 in Phase 1 development, as well as multiple discovery and pre-clinical obesity candidates; and imapextide (MBX 1416) for the treatment of PBH in Phase 2 development. The Company is based in Carmel, Indiana and Burlington, Massachusetts. To learn more, please visit the Company website at www.mbxbio.com and follow it on LinkedIn.
About MBX’s Proprietary Precision Endocrine Peptide (PEP™) Platform
MBX was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this expertise, the Company designed its proprietary Precision Endocrine Peptide™ (PEP™) platform to overcome the key limitations of unmodified and modified peptide therapies and to improve clinical outcomes and simplify disease management
for patients. PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, but are not limited to, express or implied statements regarding: MBX Biosciences’ expectations regarding the further advancement of its pipeline of programs in endocrine and metabolic disorders, including timing of initiation of a Phase 3 trial for canvuparatide in Q3 2026 and clinical data presentation at ENDO 2026 in Q2 2026; the potential for canvuparatide to be a once-weekly PTH replacement therapy; the expected timing of the Phase 1 readout for MBX 4291 and planned obesity day presentation; the timing of additional obesity candidate nominations in Q2 and Q3 2026; the potential for MBX Biosciences to develop therapies for obesity dosed once monthly; the expected timing for the Phase 2a STEADI™ trial results; the ability of MBX 1416 to be a treatment of PBH; the potential contributions of the new Chief Commercial Officer; and expectations regarding MBX Biosciences’ uses of capital, expenses and financial results, including the anticipated cash runway timing.
Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect MBX Biosciences’ business, operating results, financial condition and stock value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to the Company’s research and development activities; MBX Biosciences’ ability to execute on its strategy including obtaining the requisite regulatory approvals on the expected timeline, if at all; uncertainties relating to preclinical and clinical development activities; the Company’s dependence on third parties to conduct clinical trials, manufacture its product candidates and develop and commercialize its product candidates, if approved; MBX Biosciences’ ability to attract, integrate and retain key personnel; risks related to the Company’s financial condition and need for substantial additional funds in order to complete development activities and commercialize a product candidate, if approved; risks related to regulatory developments and approval processes of the U.S. Food and Drug Administration and comparable foreign regulatory authorities; risks related to establishing and maintaining MBX Biosciences’ intellectual property protections; risks related to the competitive landscape for MBX Biosciences’ product candidates; and final audit adjustments and other developments that may arise that would cause MBX Biosciences’ expectations with respect to the estimate of cash, cash equivalents and marketable securities as of December 31, 2025 to differ, perhaps materially, from the financial results that will be reflected in MBX Biosciences’ audited consolidated financial statements for the fiscal year ended December 31, 2025; as well as other risks described in “Risk Factors,” in MBX Biosciences’ Quarterly Report on Form 10-Q for the three months ended March 31, 2026, Annual Report on Form 10-K for the year ended December 31, 2025, as well as subsequent filings filed with the Securities and Exchange Commission (SEC). MBX Biosciences expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law, and claims
the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.
MBX Biosciences uses and intends to continue to use its Investor Relations website as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor the Company's Investor Relations website, in addition to following the Company's press releases, SEC filings, public conference calls, presentations, and webcasts.
Media Contact:
George Shea
We. Communications
gshea@wecommunications.com
Investor Contact:
Jim DeNike
MBX Biosciences
jdenike@mbxbio.com
MBX BIOSCIENCES, INC.
SELECTED FINANCIAL INFORMATION
|
|
(Unaudited) |
|
|||||
Statements of Operations Data: |
|
Three months ended March 31, |
|
|||||
(in thousands, except per share and per share data) |
|
2026 |
|
|
2025 |
|
||
Operating expenses |
|
|
|
|
|
|
||
Research and development |
|
$ |
18,474 |
|
|
$ |
22,405 |
|
General and administrative |
|
|
8,791 |
|
|
|
4,124 |
|
Total operating expenses |
|
|
27,265 |
|
|
|
26,529 |
|
Loss from operations |
|
|
(27,265 |
) |
|
|
(26,529 |
) |
Interest and other income, net |
|
|
3,748 |
|
|
|
2,649 |
|
Net loss |
|
$ |
(23,517 |
) |
|
$ |
(23,880 |
) |
Net loss per common share, basic and diluted |
|
$ |
(0.50 |
) |
|
$ |
(0.71 |
) |
Weighted average number of common shares |
|
|
46,576,204 |
|
|
|
33,412,386 |
|
|
|
(Unaudited) |
|
|||||
Balance Sheets Selected Financial Data: |
|
March 31, |
|
|
December 31, |
|
||
(in thousands) |
|
2026 |
|
|
2025 |
|
||
Cash, cash equivalents and marketable securities |
|
$ |
439,977 |
|
|
$ |
373,705 |
|
Working capital(1) |
|
|
433,969 |
|
|
|
366,044 |
|
Total assets |
|
|
452,701 |
|
|
|
385,144 |
|
Total liabilities |
|
|
14,945 |
|
|
|
15,921 |
|
Accumulated deficit |
|
|
(247,993 |
) |
|
|
(224,476 |
) |
Total stockholders’ equity |
|
|
437,756 |
|
|
|
369,223 |
|
(1) Working capital is defined as total current assets less total current liabilities. See our financial statements and the related notes thereto included in our Quarterly Report on Form 10-Q for the Three Months Ended March 31, 2026 and our Annual Report on Form 10-K for the Year Ended December 31, 2025 for further details regarding our current assets and current liabilities.